In an interview with Stock Day, CEO Chris Bunka of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) discussed the company’s recent achievements and its plans for the near future. Revenues are climbing, exceeding, so far in 2017, the total for all of 2016, and the potential for further increases is imminent. The company is in negotiation with at least four large pharmaceutical companies to license its technology. The smallest of these could increase revenues by $1 million; the largest could increase revenues by much, much more, according to Bunka. Getting any of these deals signed will boost the bottom line almost as much as they would raise revenues. Lexaria will be employing a lucrative licensing model that is likely to yield 90-100% of revenues as profit. The company expects to have its first major agreement wrapped up by the end of the year.
Apart from attracting the attention of big pharma, Lexaria has been working with the National Research Council (NRC) of Canada, an agency of the Canadian federal government, to explore the effects of its technology. The company has developed technology that allows non-psychoactive cannabinoids, vitamins, non-steroid anti-inflammatory drugs (NSAIDs) and nicotine to be absorbed at much higher rates. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to 60-90 minutes for current methods, and is already in use in a number of consumer products.
Lexaria recently raised $4 million in capital. The company intends to spend part of the proceeds in setting up an R&D program for nicotine. The initiative comes at an opportune time. In August, the FDA announced “a new comprehensive plan for tobacco and nicotine regulation that will serve as a multi-year roadmap to better protect kids and significantly reduce tobacco-related disease and death” (http://nnw.fm/hLdm6). The agency plans to stimulate public dialogue on lowering nicotine levels in combustible cigarettes to non-addictive levels. This is good news for Lexaria, which is hoping its technology can provide a delivery method for nicotine that is safer than smoking. As its CEO has remarked, “Regulation is great news for Lexaria.”
The interview can be heard at http://nnw.fm/9QqQ8
For more information, visit the company’s website at www.LexariaEnergy.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
